China biotech’s Cambrian explosion

Taking stock of the drug industry, from the lab to the medicine chest

December 23, 2025 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Kevin Frayer/Getty Images STAT+ | Opinion: China biotech's Cambrian explosion The sheer energy of China's biomedical ecosystem is producing something that looks like evolution on fast-forward. By Brian Finrow FDA approves pill version of Novo Nordisk's Wegovy, possibly widening access The oral version of the obesity therapy led to similar efficacy as the injectable weight loss treatment in a late-stage clinical trial. By Elaine Chen STAT+ | Trump administration to scrap federal rule requiring transparency into health AI tools  The Trump administration wants to scrap rules that require developers to disclose how AI tools to treat patients were developed and tested. By Casey Ross

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser